Invention Grant
- Patent Title: Monoclonal antibodies against claudin-18 for treatment of cancer
- Patent Title (中): 用于治疗癌症的克劳丁-18单克隆抗体
-
Application No.: US12601488Application Date: 2008-05-27
-
Publication No.: US08425902B2Publication Date: 2013-04-23
- Inventor: Ugur Sahin , Ozlem Tureci , Gunda Brandenburg , Dirk Usener
- Applicant: Ugur Sahin , Ozlem Tureci , Gunda Brandenburg , Dirk Usener
- Applicant Address: DE Mainz DE Mainz
- Assignee: Ganymed Pharmaceuticals AG,Johannes Gutenberg-Universitat
- Current Assignee: Ganymed Pharmaceuticals AG,Johannes Gutenberg-Universitat
- Current Assignee Address: DE Mainz DE Mainz
- Agency: McAndrews, Held & Malloy Ltd.
- Priority: EP07010622 20070529
- International Application: PCT/EP2008/004197 WO 20080527
- International Announcement: WO2008/145338 WO 20081204
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.
Public/Granted literature
- US20100166779A1 Monoclonal Antibodies Against Claudin-18 for Treatment of Cancer Public/Granted day:2010-07-01
Information query
